SCHEMBL4484055

SCHEMBL4484055

COc1ccc2cc(C(=O)O)c(NCCc3cccnc3)nc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 3/20 0.52
CSNK2A1 P68400 3/20 0.52
ALDH1A1 P00352 2/20 0.51
RAB9A P51151 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GLA P06280 1/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
ACP1 P24666 1/20 0.46
PTGDR Q13258 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.45
PIK3CG P48736 1/20 0.44
GPBAR1 Q8TDU6 1/20 0.44
TBXAS1 P24557 2/20 0.44
PTAFR P25105 2/20 0.44
NAMPT P43490 1/20 0.43
CSNK2B P67870 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4488036 0.90 TACR3 (0.51) CSNK2A2CSNK2A1RAB9AKDM4EGAA
SCHEMBL4492686 0.88 CSNK2A2 (0.55) CSNK2A2CSNK2A1ALDH1A1KDM4EMAPT
SCHEMBL4486308 0.88 PGK1 (0.50) CSNK2A2CSNK2A1ALDH1A1KDM4EGAA
SCHEMBL4497855 0.86 PTGDR (0.51) CSNK2A2CSNK2A1ALDH1A1KDM4EPOLB
SCHEMBL4480962 0.84 CSNK2A2 (0.48) CSNK2A2CSNK2A1ALDH1A1KDM4EPTGDR
SCHEMBL4492756 0.84 MEN1 (0.48) CSNK2A2CSNK2A1KMT2AMEN1HPGD
SCHEMBL4487805 0.84 NFKB1 (0.48) CSNK2A2CSNK2A1RAB9AACP1PTGDR
SCHEMBL4478359 0.83 PTGDR (0.46) CSNK2A2CSNK2A1ALDH1A1KDM4EGAA
SCHEMBL4484812 0.82 PTGDR (0.46) CSNK2A2CSNK2A1ALDH1A1KDM4EGAA
SCHEMBL4493553 0.82 KMT2A (0.57) ALDH1A1KDM4EGLAPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US claimed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP claimed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US claimed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP claimed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO claimed
US-7482455-B2 Chemical compounds SMITHKLINE BEECHAM CORPORATION (US) 2009-01-27 US disclosed
EP-1556379-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2007-06-13 EP disclosed
US-20060106058-A1 Chemical compounds BURGESS JOELLE L 2006-05-18 US disclosed
EP-1556379-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2005-07-27 EP disclosed
WO-2004034985-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106058-A1 Chemical compounds YARS1, DAPK3, NEK3 CSNK2A2 239/4885CSNK2A1 248/4885ALDH1A1 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.